Quotables
"Man will not fly for 50 years."
Wilbur Wright ; 1901
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7674775 | Substantially cell membrane impermeable compound and use thereof The present invention relates to a compound according to Formula (I): A-(L-Y)p, wherein A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises at least one arsenoxid... | 03/09/2010 |
| 7671032 | HCV NS-3 serine protease inhibitors Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with... | 03/02/2010 |
| 7662789 | Peptide substance restoring myocardium function The invention refers to the pharmaceutical means for the treatment of cardiovascular diseases and can be used as a substance restoring myocardium function in the course of treatment for different forms of this pathology. There is proposed a new tetrapeptide a... | 02/16/2010 |
| 7659255 | Methods of inhibiting glutamate receptors by administering the tripeptide KDI The present invention relates to a method of using biologically active peptide compounds comprising the tri-peptide motif KDI derived from the neurite outgrowth-promoting domain of laminin-1 as inhibitors of ionotropic glutamate receptors. The peptide compounds are ... | 02/09/2010 |
| 7642245 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif Compounds of the formula (I) where Ar and R are as defined herein, possess antibacterial properties. ... | 01/05/2010 |
| 7638495 | Peptides as solubilizing excipients for transforming growth factor β proteins The present invention relates to compositions comprising excipients or solubilizing agents for proteins. The invention relates to the discovery that a peptide derived from the N-terminus extension of the T266 isoform of rhBMP-2 has properties that enhance the solubi... | 12/29/2009 |
| 7635683 | Quinoxalinyl tripeptide hepatitis C virus inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 12/22/2009 |
| 7632819 | Methods and compositions for inhibiting PKC delta cleavage for treatment and prevention of neurodegeneration and apoptosis Methods and compositions are provided which inhibit the apoptotic activity associated with oxidative stress in many disease states. According to the invention, inhibition of chemical cleavage of PKCδ by caspase-3 results in reduction of apoptosis. Novel peptide inh... | 12/15/2009 |
| 7632818 | Method for treating conditions associated with the Metabolic Syndrome (Syndrome X) The present invention is directed to a method for treating individuals having inflammation or preventing inflammation in individuals at risk for inflammation, more specifically individuals with chronic inflammation as evidenced by elevated C-reactive protein, serum ... | 12/15/2009 |
| 7629319 | Heteroaryl peptidomimetics as thrombin receptor antagonists The invention is directed to novel heteroaryl peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, athe... | 12/08/2009 |
| 7625870 | Peptide substance restoring respiratory organs function The invention refers to the medicinal remedies for respiratory system diseases treatment and may be applied as a substance, capable of restoring respiratory organs functions and used for treatment of different forms of lung pathology. There is proposed a biologicall... | 12/01/2009 |
| 7622446 | Polypeptides, derivatives and uses thereof The invention provides a compound having formula X1-Arg-Xaa-Arg-X2 in which X1 and X2 are up to 30 amino acid residues and Xaa is an amino acid residue. A preferred compound is the tripeptide Arg-Glu-Arg which corresponds ... | 11/24/2009 |
| 7622447 | Use of glutathione synthesis stimulating compounds in reducing insulin resistance There is provided a method of reducing insulin resistance in a mammalian patient comprising selecting a patient suffering from insulin resistance and administering a compound which increases hepatic glutathione and a compound which increases hepatic nitric oxide. | 11/24/2009 |
| 7618945 | Heteroaryl peptidomimetics as thrombin receptor antagonists The invention is directed to novel heteroaryl peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, athe... | 11/17/2009 |
| 7615535 | Inhibiting GS-FDH to modulate no bioactivity Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase. ... | 11/10/2009 |
| 7608590 | HCV NS-3 serine protease inhibitors Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit ... | 10/27/2009 |
| 7608592 | HCV inhibitors The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceut... | 10/27/2009 |
| 7608591 | Targeted delivery to legumain-expressing cells The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells. ... | 10/27/2009 |
| 7598224 | Dual chain synthetic heparin-binding growth factor analogs The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, whic... | 10/06/2009 |
| 7592316 | Peptides as NS3-serine protease inhibitors of hepatitis C virus The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of us... | 09/22/2009 |
| 7585845 | Hepatitis C inhibitor compounds Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protea... | 09/08/2009 |
| 7576061 | Methods for preventing mitochondrial permeability transition The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maxim... | 08/18/2009 |
| 7569548 | Method of preparing peptide The present invention provides a method of preparing an intermediate for LHRH antagonists, which requires fewer steps than conventional methods and provides the intermediate in high yield and high purity. ... | 08/04/2009 |
| 7560433 | Treatment of multiple sclerosis (MS) The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or ... | 07/14/2009 |
| 7557088 | Methods and compositions for treating conditions The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for ... | 07/07/2009 |
| 7550439 | Methods for reducing oxidative damage The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net posi... | 06/23/2009 |
| 7541340 | Methods for reducing CD36 expression The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty... | 06/02/2009 |
| 7538091 | Intracellular delivery of biological effectors The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for t... | 05/26/2009 |
| 7524820 | Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology The invention provides a method for assessing or determining activity of a test compound on modulation of gene product levels comprising culturing cells, contacting at least one of the cultured cells with a lipid-rich fraction, contacting at least one of the culture... | 04/28/2009 |
| 7521427 | Peptidyl allyl sulfones The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include peptidyl allyl sulfone compositions that inhibit proteases, fo... | 04/21/2009 |
| 7507719 | Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment The invention relates to the use of peptidic conjugates containing Gly-His-Lys for producing dermatological or cosmetological compositions for stimulating hair growth or stopping hair fall. ... | 03/24/2009 |
| 7498310 | Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation Cosmetic or pharmaceutical preparations which are distinguished by an effective content of one or more monomeric or homo- or heterodimer or homo- or heterotrimeric or homo- or heterotetrameric oligopeptides, where these oligopeptides are based on a structure Val-Val... | 03/03/2009 |
| 7491703 | Tetrapeptide regulating blood glucose level in diabetes mellitus The invention refers to the field of medicine and can be applied as a substance capable of regulating glucose level while treating and preventing diabetes mellitus. There is proposed a biologically active new tetrapeptide lysyl-glutamyl-aspartyl-tryp-tophane of gene... | 02/17/2009 |
| 7491704 | Compounds for enzyme inhibition Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited b... | 02/17/2009 |
| 7485625 | Inhibitors of hepatitis C virus NS3/NS4a serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of us... | 02/03/2009 |
| 7468354 | Tissue specific prodrugs The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is ... | 12/23/2008 |
| 7465710 | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm This invention relates generally to dipeptides and tripeptides and to methods for pharmaceutical treatment of mammals using analogs of such dipeptides and tripeptides. More specifically, the invention relates to tripeptides and their analogs, to pharmaceutical compo... | 12/16/2008 |
| 7449446 | Combination product comprising melagatran and dexamethasone There is provided a combination product comprising; (A) melagatran or a pharmaceutically acceptable derivative thereof; and (B) dexamethasone or a pharmaceutically acceptable derivative there of, wherein each of components (A) and (B) is formulated in admixture with... | 11/11/2008 |
| 7449447 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure... | 11/11/2008 |
| 7446096 | Glutathione based delivery system A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a... | 11/04/2008 |